Patients on Eli Lilly's Mounjaro were more likely to lose weight and experienced larger reductions in body weight compared to those on Novo Nordisk's Ozempic.

The maker of weight-loss jabs Wegovy and Ozempic, Danish pharmaceutical giant Novo Nordisk, has reported a sharp rise in profits on the back of surging demand for the drugs. Net profits were 39.2bn kroner (£4.5bn) for the period from January to June, rising 43% from 27.5bn kroner a year earlier.

An Ozempic competitor drug has proven to be up to three times more effective for weight loss, a new study found.

Both Mounjaro (tirzepatide) and Ozempic (semaglutide) mimic the effects of the gut hormone GLP-1, which triggers insulin production, helps control appetite and slows the movement of food through the stomach.

The diabetes drug Mounjaro prompted more weight loss among overweight and obese adults than Ozempic did in a real-world setting, researchers report.

A new study found that Mounjaro, which is FDA-approved to treat type 2 diabetes but used off-label for weight loss, works better than competing weight loss medication Ozempic